Is there a relationship between conclusion of the Canadian Common Drug Review, CEDAC recommendations and reimbursement decisions?
la Fleur P, Lee KM, Vanstone SM; Health Technology Assessment International. Meeting (2nd : 2005 : Rome, Italy). Ital J Public Health. 2005; 2: 130. Canadian Coordinating Office for Health Technology Assessment, 600-865 Carling Avenue, Ottawa, Ontario, K1S 5S8 Canada Tel: (613) 226-2553 ext, Fax: (613) 226-5392, E-mail: philipl@ccohta.ca Objectives: To compare the conclusions of the reports produced by the Canadian Common Drug Review (CDR) to subsequent national recommendations and drug reimbursement decisions. Background: The CDR is a single process for reviewing the cost and effectiveness of new drugs. Manufacturers submit clinical data, which may be included the CDR’s systematic review of the available clinical evidence of the submitted drug, and a pharmacoeconomic evaluation, which is critically assessed. The Canadian Expert Drug Advisory Committee (CEDAC) uses these reports to make evidence-based listing recommendations to participating publicly funded drug plans. Methods: The CDR
Related Questions
- What is the relationship between HIPAA and the human subjects protection regulations of the Common Rule for which IRB review was established?
- Is there a relationship between conclusion of the Canadian Common Drug Review, CEDAC recommendations and reimbursement decisions?
- Does a Division have to follow the decisions and recommendations of the Review Committee?
